LV10575B - Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs - Google Patents

Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs Download PDF

Info

Publication number
LV10575B
LV10575B LVP-93-310A LV930310A LV10575B LV 10575 B LV10575 B LV 10575B LV 930310 A LV930310 A LV 930310A LV 10575 B LV10575 B LV 10575B
Authority
LV
Latvia
Prior art keywords
alkyl
halogen
mono
atoms
bromine
Prior art date
Application number
LVP-93-310A
Other languages
English (en)
Latvian (lv)
Other versions
LV10575A (lv
Inventor
Bartlett Robert
Kammerer Friedrich-Johannes
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of LV10575A publication Critical patent/LV10575A/xx
Publication of LV10575B publication Critical patent/LV10575B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/40—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Air Conditioning Control Device (AREA)
LVP-93-310A 1990-05-18 1993-05-07 Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs LV10575B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4016178 1990-05-18
DE4017020 1990-05-26
DE4017043 1990-05-26
PCT/EP1990/001800 WO1991017748A1 (fr) 1990-05-18 1990-10-24 Amides d'acide carboxylique-4 d'isoxazol et cyanamides acetiques d'hydroxyalkylidene, medicaments contenant ces composes et leur application

Publications (2)

Publication Number Publication Date
LV10575A LV10575A (lv) 1995-04-20
LV10575B true LV10575B (en) 1996-04-20

Family

ID=27201216

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-310A LV10575B (en) 1990-05-18 1993-05-07 Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs

Country Status (28)

Country Link
US (2) US5494911A (fr)
EP (1) EP0527736B1 (fr)
JP (3) JP2995086B2 (fr)
KR (1) KR100188801B1 (fr)
CN (1) CN1051074C (fr)
AT (1) ATE151633T1 (fr)
AU (2) AU649421B2 (fr)
BR (1) BR9008022A (fr)
CA (1) CA2083179C (fr)
CY (1) CY2123B1 (fr)
CZ (4) CZ290474B6 (fr)
DE (1) DE59010701D1 (fr)
DK (1) DK0527736T3 (fr)
ES (1) ES2102367T3 (fr)
FI (1) FI105683B (fr)
GR (1) GR3023638T3 (fr)
HU (1) HU222234B1 (fr)
IE (1) IE911694A1 (fr)
IL (1) IL98163A (fr)
LV (1) LV10575B (fr)
NO (1) NO180118C (fr)
NZ (1) NZ238165A (fr)
PT (1) PT97689B (fr)
RU (2) RU2142937C1 (fr)
SK (3) SK281317B6 (fr)
TW (2) TW205004B (fr)
WO (1) WO1991017748A1 (fr)
YU (1) YU48765B (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235563A (en) * 1989-10-13 1993-04-28 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical composition
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
GB9300083D0 (en) 1993-01-05 1993-03-03 Roussel Lab Ltd Chemical compounds
DK0607777T3 (da) * 1993-01-08 1999-08-16 Hoechst Ag Anvendelse af leflunomid til inhibering af interleukin 8
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
ES2124801T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion del factor de necrosis de tumores alfa.
DE59407412D1 (de) * 1993-01-08 1999-01-21 Hoechst Ag Verwendung von Leflunomid zur Hemmung von Interleukin 1 alpha
TW314467B (fr) * 1993-03-31 1997-09-01 Hoechst Ag
GB9313365D0 (en) * 1993-06-29 1993-08-11 Roussel Lab Ltd Chemical compounds
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
GB9322781D0 (en) * 1993-11-04 1993-12-22 Roussel Lab Ltd Aromatic amides
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
GB9520092D0 (en) * 1995-10-02 1995-12-06 Hoechst Roussel Ltd Chemical compounds
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
EP0795334B1 (fr) * 1996-03-12 2006-02-01 Sanofi-Aventis Deutschland GmbH Prodrogues pour le traitement des tumeurs et des maladies inflammatoires
DE19610955A1 (de) * 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
EA002113B1 (ru) 1996-09-04 2001-12-24 Пфайзер Инк. Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно)
DE19702988A1 (de) 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
EP1012150A4 (fr) * 1997-05-19 2002-05-29 Sugen Inc Composes d'heteroarylcarboxamide actifs contre les etats pathologiques lies aux proteine tyrosine kinases
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
EP0903345B1 (fr) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Forme cristalline de N-(4-trifluorométhylphényl)-5-méthylisoxazole-4-carboxamid
IL135714A0 (en) * 1997-11-04 2001-05-20 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
ATE269295T1 (de) * 1998-04-17 2004-07-15 Parker Hughes Inst Btk inhibitoren und verfahren zur identifizierung und verwendung
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
CN1411373A (zh) * 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
ES2237553T3 (es) * 2000-02-15 2005-08-01 Teva Pharmaceutical Industries Ltd. Procedimiento para la sintesis de leflunomida.
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
US20030055263A1 (en) * 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
EP1487796A4 (fr) * 2002-03-28 2005-11-16 Neurogen Corp Biarylamides substitues en tant que modulateurs du recepteur c5a
US6858637B2 (en) 2002-03-28 2005-02-22 Neurogen Corporation Substituted biaryl amides as C5a receptor modulators
WO2004035571A1 (fr) * 2002-10-15 2004-04-29 Rigel Pharmaceuticals, Inc. Indoles substitues et leur utilisation en tant qu'inhibiteurs du virus de l'hepatite c (vhc)
RU2280464C2 (ru) * 2004-03-22 2006-07-27 Александр Иванович Петенко Способ получения сухого пробиотического препарата "бацелл"
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
MXPA06014754A (es) 2004-06-17 2007-06-22 Infinity Pharmaceuticals Inc Compuestos y metodos para inhibir la interaccion de las proteinas bcl con los componentes de enlace.
WO2006115509A2 (fr) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
DE102006014165A1 (de) * 2006-03-24 2007-09-27 Schebo Biotech Ag Neue Isooxazol-Derivate und deren Verwendungen
AU2007275301A1 (en) * 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
CA2684105C (fr) * 2007-05-03 2011-09-06 Pfizer Limited Derives de la pyridine
US20090076275A1 (en) * 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
MY159575A (en) 2009-04-02 2017-01-13 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
EP2236505A1 (fr) * 2009-04-03 2010-10-06 Bayer CropScience AG Aminopyridines et pyridazines acylés en tant qu'insecticides
WO2011004282A2 (fr) 2009-07-09 2011-01-13 Alembic Limited Nouvelle forme polymorphe de sels de teriflunomide
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
JP5820476B2 (ja) 2010-08-24 2015-11-24 アルギアックス ファルマコウティカルス ゲーエムベーハーＡＬＧＩＡＸ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＧｍｂＨ レフルノミドおよびマロノニトリラマイドの新規の使用
PT2632451T (pt) 2010-10-29 2017-12-14 Algiax Pharmaceuticals Gmbh Utilização de malononitrilamidas na dor neuropática
WO2012110911A1 (fr) 2011-02-18 2012-08-23 Alembic Pharmaceuticals Limited Nouvelle forme polymorphe de tériflunomide
US20140057978A1 (en) 2011-03-17 2014-02-27 Algiax Pharmaceuticals Gmbh Novel use of benzofuranylsulfonates
EP2685983B1 (fr) 2011-03-17 2016-05-18 Algiax Pharmaceuticals GmbH Nouvelle utilisation d'imidazotriazinones
RS57962B1 (sr) 2013-02-25 2019-01-31 Aurigene Discovery Tech Ltd Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze
WO2015029063A2 (fr) * 2013-08-30 2015-03-05 Msn Laboratories Private Limited Nouveau polymorphe de (4-trifluorométhyl-phényl)-amide d'acide (z)-2-cyano-3-hydroxy-but-2-énoïque et son procédé de préparation
EP3071199A2 (fr) 2013-11-22 2016-09-28 Genzyme Corporation Nouvelles méthodes pour traiter des maladies neurodégénératives
LT3466955T (lt) 2014-01-13 2021-02-25 Aurigene Discovery Technologies Limited Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas
AU2015275730A1 (en) * 2014-06-20 2016-12-15 Aurigene Discovery Technologies Limited Substituted indazole compounds as IRAK4 inhibitors
CN105272882B (zh) * 2014-07-23 2019-05-31 欣凯医药化工中间体（上海）有限公司 一种环保简便制备泰瑞米特的方法
US10526279B2 (en) 2015-06-17 2020-01-07 Biocon Limited Process for the preparation of teriflunomide
BR112019017567A2 (pt) 2017-02-24 2020-03-24 Merck Patent Gmbh Derivados de 1,4,6-trissubstituído-2-alquil-1h-benzo[d]imidazol como inibidores da di-hidro-orotato oxigenase
EP3600270B1 (fr) 2017-03-31 2023-06-14 Aurigene Oncology Limited Composés et compositions pour le traitement de troubles hématologiques
HRP20211462T1 (hr) 2017-04-24 2021-12-24 Aurigene Discovery Technologies Limited Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
HUE067356T2 (hu) 2017-10-31 2024-10-28 Curis Inc IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra
TR202022336A2 (tr) 2020-12-30 2022-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet comprising teriflunomide
EP4319750A4 (fr) 2021-04-08 2025-02-26 Curis, Inc. Polythérapies pour le traitement du cancer
EP4162933A1 (fr) 2021-10-08 2023-04-12 Algiax Pharmaceuticals GmbH Composé pour le traitement de la stéatose hépatique non alcoolique et des maladies associées
CN117126078B (zh) * 2022-05-19 2025-11-25 四川大学 一类化合物及在治疗hDHODH介导的疾病中的用途
EP4382097A1 (fr) 2022-11-25 2024-06-12 Sanovel Ilac Sanayi Ve Ticaret A.S. Comprimé comprenant du tériflunomide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
ES448386A1 (es) * 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2557003A1 (de) * 1975-12-18 1977-06-23 Hoechst Ag Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
DE2555789A1 (de) * 1975-12-11 1977-07-07 Hoechst Ag Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
DE2655009A1 (de) * 1976-12-04 1978-06-15 Hoechst Ag Isoxazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3405727A1 (de) * 1984-02-17 1985-08-22 Hoechst Ag, 6230 Frankfurt Isoxazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
GB8619432D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
GB8619433D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
US4816467A (en) * 1987-01-09 1989-03-28 Farmitalia Carlo Erba S.R.L Heteroaryl 3-oxo-propanenitrile derivatives, pharmaceutical compositions and use

Also Published As

Publication number Publication date
PT97689B (pt) 1998-09-30
NO924433L (no) 1992-11-17
JPH11343285A (ja) 1999-12-14
ATE151633T1 (de) 1997-05-15
IE911694A1 (en) 1991-11-20
RU2084223C1 (ru) 1997-07-20
GR3023638T3 (en) 1997-08-29
JP3201747B2 (ja) 2001-08-27
CZ290474B6 (cs) 2002-07-17
ES2102367T3 (es) 1997-08-01
PT97689A (pt) 1992-02-28
CA2083179A1 (fr) 1991-11-19
CN1056684A (zh) 1991-12-04
NO180118B (no) 1996-11-11
FI925211A0 (fi) 1992-11-17
TW205004B (fr) 1993-05-01
YU88491A (sh) 1995-03-27
DE59010701D1 (de) 1997-05-22
AU649421B2 (en) 1994-05-26
NO180118C (no) 1997-02-19
EP0527736A1 (fr) 1993-02-24
US5532259A (en) 1996-07-02
CZ290736B6 (cs) 2002-10-16
HU222234B1 (hu) 2003-05-28
FI925211L (fi) 1992-11-17
IL98163A (en) 1996-01-31
AU662465B2 (en) 1995-08-31
CZ290737B6 (cs) 2002-10-16
EP0527736B1 (fr) 1997-04-16
WO1991017748A1 (fr) 1991-11-28
SK281318B6 (sk) 2001-02-12
RU94033835A (ru) 1996-04-20
NZ238165A (en) 1994-08-26
CA2083179C (fr) 2001-10-23
CS145091A3 (en) 1992-01-15
CY2123B1 (en) 2002-06-21
YU48765B (sh) 1999-11-22
JP3233610B2 (ja) 2001-11-26
JPH11322700A (ja) 1999-11-24
US5494911A (en) 1996-02-27
AU6546890A (en) 1991-12-10
LV10575A (lv) 1995-04-20
CZ290717B6 (cs) 2002-10-16
DK0527736T3 (da) 1997-10-20
JP2995086B2 (ja) 1999-12-27
AU5799294A (en) 1994-07-07
BR9008022A (pt) 1993-04-06
NO924433D0 (no) 1992-11-17
RU2142937C1 (ru) 1999-12-20
FI105683B (fi) 2000-09-29
HUT64314A (en) 1993-12-28
HU9203619D0 (en) 1993-03-29
TW211558B (fr) 1993-08-21
CN1051074C (zh) 2000-04-05
JPH05506425A (ja) 1993-09-22
IL98163A0 (en) 1992-06-21
KR100188801B1 (ko) 1999-06-01
SK281316B6 (sk) 2001-02-12
SK281317B6 (sk) 2001-02-12

Similar Documents

Publication Publication Date Title
LV10575B (en) Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
DE60026822T2 (de) -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
AU670816B2 (en) N-cyano-N'-pyridylguanidines as serotonin antagonists
WO2015038778A1 (fr) Activateurs substitués de l'urée-kinase eif2α
JP2008513508A (ja) 炎症及び免疫に関連する用途に用いる化合物
JPH0150700B2 (fr)
DE3889057T2 (de) Verbindungen für die Induktion der in vitro- und in vivo-Erzeugung von Cytokinen.
JPS6259264A (ja) ５−ピリミジンカルボキサミド、それらの製造法およびそれらからなる医薬組成物
CH634566A5 (de) Benzylpyrimidine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
US4371697A (en) 3-[1-(Hydroxymethyl)-2-phenylethyl]-N-[(phenylamino)-carbonyl]sydnone imine
US3803229A (en) Amides of 1-aminocyclopentane-carboxylic acid
US4289885A (en) 3-[2-(Dimethylamino)-2-phenylethyl]N-[phenylamino)carbonyl]sydnone imine, a new central nervous system stimulant
DE2600069A1 (de) Pharmazeutische praeparate
FI105680B (fi) Menetelmä terapeuttisesti käyttökelpoisten hydroksialkylideenisyaanietikkahappoamidien valmistamiseksi
BR112014017190B1 (pt) compostos com atividade antibacteriana, procedimento para a sua obtenção e composições farmacêuticas que fazem parte desses compostos
EP0050916A2 (fr) Stimulants du SNC et agents antihypertensifs
JP2023518968A (ja) スフィンゴシン１ホスフェート受容体モジュレーター
DE2600070A1 (de) Pharmazeutische kombinationspraeparate